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Abstract: The wide variety of anticoagulant and antiplatelet agents available for clinical 
use has made choosing the optimal antithrombotic regimen for patients with acute coronary 
syndromes undergoing percutaneous coronary intervention a complex task. While there is no 
single best regimen, from a risk-benefit ratio standpoint, particular regimens may be considered 
optimal for different patients. We review the mechanisms of action for the commonly prescribed 
antithrombotic medications, summarize pertinent data from randomized trials on their use in 
acute coronary syndromes, and provide an algorithm (incorporating data from these trials as 
well as risk assessment instruments) that will help guide the decision-making process.
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Introduction
In the early days of percutaneous coronary intervention (PCI) the armamentarium 
of antithrombotic agents was limited; therefore, the decision on what agent(s) to 
administer was fairly straightforward. The wide variety of anticoagulant and antiplatelet 
agents available for clinical use now has made this decision-making process much 
more complex, and at times even confusing. While there is no single best choice for an 
antithrombotic regimen in patients with acute coronary syndromes (ACS) undergoing 
PCI, from a risk-benefit ratio standpoint, a particular regimen may be better for an 
individual patient. Because early invasive strategies with coronary angiography and PCI 
are preferred for certain patients with unstable angina, non-ST elevation myocardial 
infarction (STEMI),1–4 and STEMI,5 the scope of this issue is considerable. Nearly 
8 million people are diagnosed with an ACS annually in the United States alone, and 
an estimated 1.3 million undergo a PCI procedure.6 Importantly, up to 15% of patients 
undergoing PCI develop a major bleeding complication,7,8 which results in higher rates 
of short- and long-term mortality.7,8 The evidence supporting a causal relationship 
between major bleeding and excess mortality in patients undergoing PCI (including 
the potential mechanisms involved) has been recently reviewed.9
Decisions on the choice of antithrombotic regimen, therefore, should be 
individualized, and take into consideration both the risk of a recurrent cardiac event as 
well as the risk of a bleeding complication. We will review the mechanisms of action 
for the commonly prescribed antithrombotic medications, summarize pertinent data 
from randomized trials regarding their use in ACS, and provide an algorithm that will 
help physicians choose the most effective and safest regimen for an individual patient 
with an ACS undergoing PCI.
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Antithrombotic agents – mechanisms 
of action
Patients presenting with ACS who undergo PCI benefit from 
a combination of antiplatelet and anticoagulant medications.10 
From a pathophysiologic standpoint, the inciting event for 
an ACS is endothelial injury (plaque rupture or erosion): 
subsequent activation of platelets and the coagulation 
cascade results in thrombus formation.11,12 If this process is 
not interrupted, total occlusion of the coronary artery may 
occur, resulting in a myocardial infarction. Since platelet 
adhesion, activation, and aggregation comprise the initial 
stage in thrombus formation, antiplatelet agents (aspirin, 
thienopyridines, and platelet glycoprotein IIb/IIIa inhibitors) 
are critically important. Additionally, anticoagulant agents 
(indirect and direct thrombin inhibitors, and factor Xa 
inhibitor) also play a key role in the pathophysiologic process 
by limiting clot formation and propagation, particularly 
during the PCI procedure itself.
Antiplatelet agents
Antiplatelet medications (aspirin, thienopyridines, and 
platelet glycoprotein IIb/IIIa inhibitors) are commonly used 
alone or in combination with other antithrombotic medica-
tions in patients with ACS undergoing PCI. We will briefly 
review their mechanisms of action.
Aspirin
Aspirin permanently and irreversibly blocks cyclooxygenase-1 
for the lifespan of the platelet, inhibits the synthesis of throm-
boxane A2, and is a mainstay of therapy for patients with 
ACS. It has been shown to improve clinical outcomes13–16 and 
unless contraindicated, should be administered to all patients 
with ACS, including those undergoing PCI.
Thienopyridines
Clopidogrel and ticlopidine are structurally related thienopyr-
idines that selectively inhibit adenosine diphosphate (ADP)-
induced platelet aggregation. They block the binding of ADP 
to the receptor P2Y12, thus inhibiting activation of  the platelet 
glycoprotein IIb/IIIa complex and platelet activation.17 
A higher side effect profile of ticlopidine, including diarrhea, 
nausea, and vomiting in up to 50% of patients,18 and serious 
hematologic complications such as neutropenia in 1.0% 
to 2.4% of patients,19 and thrombotic thrombocytopenic 
purpura20 has led to the primary use of clopidogrel in ACS. 
Prasugrel, a third generation thienopyridine recently approved 
by the United States Food and Drug Administration, is a 
more potent blocker of the platelet P2Y12 receptor than 
clopidogrel.21 However, it has also been associated with 
increased risk of bleeding particularly in patients 75 years 
of age, in patients who weigh 60 kg, and in those with a 
history of transient ischemic attacks or strokes.22
Platelet glycoprotein iib/iiia inhibitors
Platelet activation leads to a conformational change in the 
glycoprotein IIb/IIIa receptor. Platelet glycoprotein IIb/IIIa 
inhibitors bind to and block the conformationally modified 
receptor, significantly blocking platelet aggregation. These 
agents can be divided into two groups:23 (1) monoclonal 
antibodies that block the receptor (abciximab), and (2) natural 
or synthetic compounds that contain a sequence of amino 
acids recognized by the receptor that act as competitive 
inhibitors (tirofiban and eptifibatide). While all three agents 
are indicated as adjunctive agents in patients undergoing 
PCI, only eptifibatide and tirofiban are approved for use in 
patients presenting with a non-STEMI who do not undergo 
an early invasive strategy.
Anticoagulant agents
Anticoagulant medications are also used alone or in 
combination with antiplatelet medications in patients with 
ACS undergoing PCI. These agents include indirect thrombin 
inhibitors (unfractionated and low-molecular-weight 
heparin), direct thrombin inhibitors (bivalirudin), and factor 
Xa inhibitor (fondaparinux).
indirect thrombin inhibitors
The heparins, both unfractionated and low molecular weight, 
are indirect thrombin inhibitors. These agents complex with 
antithrombin and inhibit fibrin formation, as well as clot 
production and propagation. Unfractionated heparin has been 
the primary parenteral anticoagulant used in patients with 
ACS. It targets the coagulation factors IIa (thrombin) and 
Xa, with additional but less significant activity against factors 
IXa, XIa, and XIIa.24 Unfractionated heparin inactivates 
thrombin by forming a complex with thrombin and anti-
thrombin, and inactivates factor Xa through antithrombin. 
Limitations to unfractionated heparin use include the need for 
frequent laboratory monitoring, neutralization of heparin’s 
activity by activated platelets,25 thrombocytopenia,26 
platelet aggregation,26 a dose-dependent risk of bleeding,27 
and rebound ischemia following its discontinuation.28–30 
Moreover, since unfractionated heparin is heterogenous 
in structure (about one-third of heparin chains contain the 
high-affinity pentasaccharide required for anticoagulant 
activity) it is also heterogeneous in its pharmacologic activity. Vascular Health and Risk Management 2009:5 679
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Thus, the efficacy and safety of low-molecular-weight heparin 
has been studied in patients with ACS as an alternative to 
unfractionated heparin.
Low-molecular-weight heparins are fragments of 
unfractionated heparin formed via depolymerization reac-
tions that result in polysaccharides of smaller size. Low-
molecular-weight heparin has greater anti-Xa than anti-IIa 
activity. Importantly, it does not require monitoring of 
clotting times, is less inhibited by activated platelets,25 and 
is associated with a lower incidence of heparin-induced 
thrombocytopenia31 and rebound ischemia following its 
discontinuation.29 Since it binds less avidly to heparin-
binding proteins than does unfractionated heparin, it has 
better bioavailability and a more predictable anticoagulant 
response. Of the low-molecular-weight heparins clinically 
available, enoxaparin is by far the most widely used. It has 
been shown to decrease ischemic complications in patients 
treated both conservatively and invasively.32
Direct thrombin inhibitors
The direct thrombin inhibitors, hirudin, argatroban and 
bivalirudin directly bind to thrombin (factor IIa) without 
the need for antithrombin. Compared to indirect thrombin 
inhibitors, they have a more predictable anticoagulant 
response, do not require anticoagulant monitoring, and are able 
to inactivate fibrin-bound as well as fluid-phase thrombin.33,34 
Importantly, because they do not bind to platelet factor 4, they 
do not cause heparin-induced thrombocytopenia. Hirudin 
and argatroban are approved for the treatment of patients 
with heparin-induced thrombocytopenia;35,36 bivalirudin is 
approved as an alternative to heparin in patients with ACS 
and in patients undergoing PCI.
Factor Xa inhibitor
Fondaparinux is a synthetic analog of the antithrombin-
binding pentasaccharide sequence found in heparin. It is 
the only selective factor Xa inhibitor available for clinical 
use. It binds to and produces a conformational change in 
antithrombin, markedly increasing its anti-factor Xa activity, 
but has no activity against thrombin. Fondaparinux does 
not require monitoring of coagulation, which results in 
more predictable and sustained anticoagulation compared 
to heparin. Additionally, since it does not bind to platelets 
or to platelet factor 4, it does not cause heparin-induced 
thrombocytopenia. Because it is cleared by the kidneys, it is 
contra-indicated in patients with a CrCl  30 ml/min. The 
American College of Cardiology/American Heart Association 
(ACC/AHA) recommends its use for patients with ACS who 
are undergoing an early invasive or conservative strategy.37 
However, in patients undergoing PCI its use has been associ-
ated with high rates of catheter thrombosis, making the addi-
tion of unfractionated heparin mandatory in this setting.38
Reversal of agents
If a patient does experience a serious bleeding episode, 
in addition to discontinuation of antithrombotic agents, 
several antidotes are available for clinical use to help stop 
the bleeding and stabilize the patient. In patients in whom 
unfractionated heparin has been given protamine sulfate 
can be administered. Protamine sulfate is administered 
intravenously at a rate that should not exceed 50 mg over 
10 minutes because of the risk of histamine release resulting 
in hypotension, bradycardia, and bronchospasm.39 The newer 
agents including low-molecular-weight heparin, the factor Xa 
inhibitor, fondaparinux, and the direct thrombin inhibitors 
do not have specific antidotes. While protamine sulfate is a 
specific and effective antidote for unfractionated heparin, 
it only partially neutralizes the anticoagulant effect of low-
molecular-weight heparin (approximately 60% of the antico-
agulant effect), and therefore its use may result in failure to 
stop the bleeding.40 Recombinant factor VIIa has been shown 
to reverse the anticoagulant effect of fondaparinux, however, 
one important caveat is that this reversal effect was shown 
in healthy volunteers, not in patients with ACS.41 In experi-
mental models, recombinant factor VIIa, prothrombin com-
plex concentrates, and desmopressin acetate have all been 
studied as to their ability to reverse the anticoagulant effect 
of the direct thrombin inhibitors.39 Lastly, hemodialysis, 
hemoperfusion, and plasmapheresis may be indicated in 
some cases of severe bleeding.42
Data from the randomized trials
Over the last decade, many randomized trials have been 
performed to evaluate the efficacy and safety of antithrom-
botic therapies. We will summarize pertinent data regarding 
their use in patients with ACS undergoing PCI.
Role of thienopyridines
In trials comparing ticlopidine to clopidogrel in combination 
with aspirin following intracoronary stent placement, clopi-
dogrel was not only as effective as ticlopidine, but had a 
superior safety and tolerability profile.43–45 These positive 
findings for clopidogrel, together with the serious risk of 
neutropenia with ticlopidine,46 has led to the virtual discon-
tinuation of ticlopidine administration: used only in the rare 
patient who is intolerant to clopidogrel.Vascular Health and Risk Management 2009:5 680
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It has become increasingly clear that, in addition to 
aspirin, the early administration of clopidogrel is key since 
optimal pretreatment with this medication has been shown 
to significantly influence clinical outcomes in patients with 
ACS treated both conservatively47 and invasively.48,49 Hence, 
clopidogrel carries a Class I (level of evidence: A) indication 
for all patients with ACS according to the ACC/AHA guide-
lines.37 Moreover, pretreatment (or lack of pretreatment) with 
clopidogrel influences the decision as to which antithrom-
botic regimen to choose for patients undergoing PCI. The 
original study demonstrating the importance of clopidogrel 
therapy in patients with ACS undergoing PCI was the PCI-
Clopidogrel in Unstable Angina to Prevent Recurrent Events 
(CURE) study.48 Of the 2658 patients undergoing PCI in this 
study, those who were pre-treated with 300 mg of clopido-
grel had a 31% relative risk reduction in cardiovascular death 
or myocardial infarction at long-term (8-month) follow-up 
compared to those treated with placebo (8.8% vs 12.6%, 
P = 0.002). Importantly, there was no significant difference 
in rates of major bleeding between the two groups (2.7% vs 
2.5%, P = 0.64). The benefit of clopidogrel administration 
is also evident in ACS patients who require coronary artery 
bypass surgery (CABG) following diagnostic coronary 
angiography. An analysis from the Acute Catheterization 
and Urgent Intervention Triage Strategy (ACUITY) study 
showed that patients who received clopidogrel prior to 
CABG had lower rates of the composite endpoint of death, 
myocardial infarction, or unplanned revascularization at 
30 days compared to those who did not receive clopidogrel 
(12.7% vs 17.3%, P = 0.01).50 Moreover, there was no 
difference in rates of post-surgical major bleeding (50.3% vs 
50.9%, P = 0.83).
In addition to the length of time prior to PCI the loading 
dose of clopidogrel is administered, the dosage (conventional 
300 mg or high dose 600 mg) is also important. It has been 
shown that some patients exhibit incomplete inhibition of 
ADP-induced platelet aggregation within 24 hours of a 
300 mg loading dose of clopidogrel.51 Thus, the risks and 
benefits of administering a higher loading dose of clopidogrel 
(600 mg) have been examined. In one study, 292 patients 
were randomized to either a 300 mg or 600 mg loading dose 
of clopidogrel at least 12 hours prior to PCI.52 ADP-induced 
platelet aggregation was significantly lower in patients 
who received 600 mg of clopidogrel compared to those 
who received 300 mg of clopidogrel. Moreover, there were 
significantly fewer cardiovascular events in the group that 
received the 600 mg loading dose of clopidogrel compared 
to the 300 mg loading dose (5.0% vs 12.0%, P = 0.02). 
The benefit of a higher loading dose of clopidogrel was also 
seen in the Platelet Responsiveness to Aspirin and Clopidogrel 
and Troponin Increment after Coronary Intervention in Acute 
Coronary Lesions (PRACTICAL) trial.53 In this trial patients 
who were randomized to 600 mg of clopidogrel had signifi-
cantly reduced ADP-induced platelet aggregation compared 
to those who were randomized to 300 mg. However, there 
was no difference in clinical outcomes at 6 months – the 
high rate (69%) of concomitant platelet glycoprotein IIb/IIIa 
inhibitor use may have attenuated the effect of the higher 
loading dose of clopidogrel. The Antiplatelet Therapy for 
Reduction of Myocardial Damage During Angioplasty 
(ARMYDA)-2 trial randomized 255 patients undergoing PCI 
to either a 600 mg loading dose or a 300 mg loading dose of 
clopidogrel 4 to 8 hours prior to the procedure.54 The primary 
endpoint (a 30-day composite of death, myocardial infarction, 
or target vessel revascularization) was significantly lower in 
patients who received the high loading dose of clopidogrel 
compared to those who received the conventional loading 
dose (4% vs 12%, P = 0.041), and was driven by a signifi-
cantly lower rate of myocardial infarction: on multivariate 
analysis the high loading dose of clopidogrel was associated 
with a 50% risk reduction of infarction (odds ratio [OR] 0.48, 
95% confidence interval [CI] 0.15–0.97, P = 0.044).
Prasugrel, a third generation thienopyridine, has been 
recently studied in patients with acute coronary syndromes in 
the Trial to Assess Improvement in Therapeutic Outcomes by 
Optimizing Platelet Inhibition with Prasugrel-Thrombolysis 
in Myocardial Infarction (TRITON-TIMI)-38 trial.22 In this 
trial, 13,608 patients with moderate to high risk acute coronary 
syndromes scheduled to undergo PCI were randomized to 
prasugrel (60 mg loading dose and a 10 mg daily maintenance 
dose) or to clopidogrel (300 mg loading dose and a 75 mg 
daily maintenance dose) for 6 to 15 months. Patients who 
were randomized to prasugrel were less likely to experience 
the primary endpoint (a combined endpoint of death, nonfatal 
myocardial infarction, or nonfatal stroke; 9.9% vs 12.1%, 
P  0.001). However, major bleeding (including fatal 
bleeding) was significantly increased in patients who received 
prasugrel compared to clopidogrel (2.4% vs 1.8%, P = 0.03). 
In a prespecified subgroup analysis of patients presenting with 
STEMI,55 prasugrel treatment again was associated with a 
significant decrease in the primary endpoint (6.5% vs 9.5%, 
P = 0.0017), however, there was no difference in rates of 
major bleeding between patients randomized to prasugrel vs 
clopidogrel (1.0% vs 1.3%, P = 0.34). Lastly, in a separate 
substudy of patients who underwent coronary artery stenting, 
patients who were randomized to prasugrel had significant Vascular Health and Risk Management 2009:5 681
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decreases not only in the primary endpoint (9.7% vs 
11.9%, P = 0.0001), but also the rate of stent thrombosis 
(1.13% vs 2.35%, P  0.0001).56 The TRITON-TIMI 38 trial 
is a perfect example of the balancing act between achieving 
improved ischemic outcomes and decreasing bleeding 
complications, and underscores the importance of patient 
selection and individualizing antithrombotic therapy.
Role of platelet glycoprotein iib/iiia inhibitors
Abciximab was the first platelet glycoprotein IIb/IIIa inhibitor 
available for clinical use. Several trials showed improved 
clinical outcomes in patients with ACS undergoing PCI who 
were treated with abciximab vs control;57–62 however, its use 
was associated with significant bleeding complications in 
many of these trials.57,60 Trials assessing the safety and effi-
cacy of tirofiban and integrilin have shown mixed results with 
no significant differences in clinical outcomes in some,63,64 
and improved clinical outcomes in others.65–67
An important complication of platelet glycoprotein 
IIb/IIIa inhibitors that limits widespread use of these agents 
is the increased risk of bleeding.68 Although a meta-analysis 
of 6 trials, enrolling 31,402 patients with ACS who were 
not routinely scheduled for early revascularization showed 
a 9% reduction in the rate of death or myocardial infarction 
at 30-day follow-up in patients randomized to platelet 
glycoprotein IIb/IIIa inhibitors compared with placebo 
(10.8% vs 11.8%, OR 0.91, 95% CI 0.84–0.98, P = 0.015), 
major bleeding complications were increased in patients who 
received them (2.4% vs 1.4%, P  0.0001).69 One caveat 
regarding these results is that the improved clinical outcomes 
provided by these agents were confined to ACS patients with 
elevated troponin levels.
Questions  remain  about  the  choice  of  platelet 
glycoprotein IIb/IIIa inhibitor due to conflicting results 
from comparative studies. In the Tirofiban and Reopro Give 
Similar Efficacy Outcomes (TARGET) trial70 the primary 
endpoint (a composite of death, myocardial infarction, or 
target vessel revascularization at 30 days) occurred more 
frequently in the patients randomized to tirofiban compared 
to those randomized to abciximab (7.6% vs 6.0%, P = 0.038). 
However, in the Multicentre Evaluation of Single High 
Dose Bolus Tirofiban vs Abciximab with Sirolimus-Eluting 
Stent or Bare Metal Stent in Acute Myocardial Infarction 
(MULTISTRATEGY) trial,71 there was no difference 
in ST segment resolution between patients treated with 
abciximab or tirofiban (Relative Risk [RR] 1.02, 97.5% 
CI 0.958–1.086, P  0.001 for noninferiority). Moreover, 
ischemic and bleeding complications were similar between 
the groups. Lastly, a recent meta-analysis of randomized 
trials comparing abciximab vs eptifibatide and tirofiban in 
primary PCI found no significant differences in angiographic, 
electrocardiographic or clinical outcomes (including bleeding 
complications) between abciximab and the use of either 
eptifibatide or tirofiban.72
Because clopidogrel therapy plays a critical therapeutic 
role in patients with ACS, some investigators have asked 
whether platelet glycoprotein IIb/IIIa inhibitors add sufficient 
clinical benefit when superimposed upon a background of 
aspirin, heparin, and clopidogrel. One of the first studies to 
examine this question was the Intracoronary Stenting and 
Antithrombotic Regimen-Rapid Early Action for Coronary 
Treatment (ISAR-REACT)-2 study.73 This study random-
ized 2022 high-risk patients with ACS undergoing PCI 
to either abciximab therapy (bolus + 12-hour infusion) or 
placebo. Importantly, all patients were optimally pretreated 
with 600 mg of clopidogrel (at least 2 hours prior to the 
procedure) in addition to aspirin and unfractionated heparin. 
There was a 25% relative risk reduction in the primary end 
point (a composite of death, myocardial infarction, or urgent 
target vessel revascularization occurring within 30 days) in 
the patients treated with abciximab (8.9% vs 11.9%; RR 0.75, 
95% CI 0.58–0.97, P = 0.03). Moreover, there were no dif-
ferences in rates of major or minor bleeding, or in the need 
for blood transfusion. However, at 30 days a pre-specified 
analysis showed that the significant benefit was confined 
to the patients who had elevated troponin levels, a finding 
consistent with a previously published meta-analysis.69
In the Early or Late Intervention in Unstable Angina 
(ELISA)-2 trial, 328 consecutive patients with ACS were 
randomized to pretreatment with dual antiplatelet therapy 
(aspirin and clopidogrel 600 mg) or triple antiplatelet therapy 
(aspirin, clopidogrel 300 mg, and tirofiban).74 The primary 
endpoint was enzymatic infarct size, with a prespecified sec-
ondary endpoint of Thrombolysis in Myocardial Infarction 
(TIMI) flow on the initial angiogram. Although rates of 
TIMI 3 flow on the initial angiogram were significantly 
higher in patients who were treated with triple antiplatelet 
therapy (67 vs 47%, P = 0.002), there was no difference 
in the primary endpoint of enzymatic infarct size (median, 
interquartile range): 166 IU/L (60–349) in the triple antiplate-
let group vs 193 IU/L (75–466) in the dual antiplatelet group, 
P = 0.2. Additionally, there was no significant difference in 
bleeding rates between the groups.
More recently, the Early Versus Delayed, Provisional 
Eptifibatide in Acute Coronary Syndromes (EARLY-ACS) 
trial compared the safety and efficacy of early, routine Vascular Health and Risk Management 2009:5 682
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administration of eptifibatide (2 boluses and a 12-hour infusion 
prior to angiography) to delayed, provisional administration 
of eptifibatide in 9492 patients with unstable angina or 
non-STEMI who were undergoing PCI.75 Importantly, 75% 
of the patients were pretreated with 300 mg of clopidogrel. 
There was no difference in the primary endpoint (a composite 
of death, myocardial infarction, recurrent ischemia requiring 
urgent revascularization, or the occurrence of a thrombotic 
complication during PCI that required bolus therapy opposite 
to the initial study group assignment at 96 hours) between the 
groups (9.3% in the early eptifibatide group, and 10.0% in 
the delayed eptifibatide group, OR 0.92, 95% CI 0.80–1.06, 
P = 0.23). Moreover, there was no difference in the rate of 
death or myocardial infarction at 30 days between the early 
and delayed eptifibatide groups, with or without the presence 
of troponin elevation. However, patients randomized to early 
eptifibatide had a statistically significant increase in TIMI major 
hemorrhage (2.6% vs 1.8%, P = 0.02), and an increased need 
for blood transfusions (8.6% vs 6.7%, P = 0.001). Thus, these 
results indicate that the routine early administration of platelet 
glycoprotein IIb/IIIa inhibitors in patients with unstable angina 
and non-STEMI prior to PCI is not recommended. Moreover, 
in non-STEMI patients who are optimally pre-treated with 
clopidogrel, the addition of platelet glycoprotein IIb/IIIa 
inhibitors is unlikely to add significant clinical benefit. Hence, 
the ACC/AHA guidelines state that for non-STEMI patients in 
whom an initial invasive approach is selected, it is reasonable 
to omit the upstream use of a platelet glycoprotein IIb/IIIa 
inhibitor if bivalirudin is used and if at least 300 mg of 
clopidogrel was administered at least 6 hours prior to the 
planned procedure (Class IIa, level of evidence: B).37
The data supporting the addition of upstream platelet 
glycoprotein IIb/IIIa inhibitors to high dose clopidogrel in 
patients presenting with STEMI is conflicting. In the Bavarian 
Reperfusion Alternatives Evaluation (BRAVE) 3 trial,76 8000 
patients with STEMI received a 600 mg loading dose of 
clopidogrel and were then randomized to upstream abciximab 
or placebo prior to PCI. There was no difference in the primary 
endpoint of infarct size between the two groups. Moreover, 
there was no difference in the composite endpoint of death, 
recurrent infarction, stroke, or urgent revascularization 
between those randomized to abciximab compared to 
placebo (5.0% vs 3.8%, P = 0.40). In the Ongoing Tirofiban 
in Myocardial Evaluation (On-TIME) 2 trial,65 984 patients 
with STEMI were randomized to either a high-dose bolus 
of tirofiban or placebo in addition to high dose clopidogrel 
(600 mg), aspirin, and heparin. Patients who were pretreated 
with tirofiban had significantly better ST segment resolution 
compared to those who received placebo. The combined 
endpoint of death, recurrent infarction, urgent target vessel 
revascularization, or blinded bail-out use of tirofiban was 
significantly decreased in those who received tirofiban com-
pared to placebo (26.0% vs 32.9%, P = 0.020), suggesting that 
further platelet inhibition in addition to high dose clopidogrel 
is important in patients with STEMI undergoing PCI.
In order to decrease the rates of bleeding complications 
while still benefiting from their use, several studies have 
evaluated alternate ways to administer platelet glycoprotein 
IIb/IIIa inhibitors. One such study called the Brief Infusion of 
Eptifibatide Following Percutaneous Coronary Intervention 
(BRIEF-PCI) trial examined whether an abbreviated infusion 
of eptifibatide was safe following a successful, non-emergent 
PCI.77 A total of 624 patients with stable angina, unstable 
angina, or recent STEMI who underwent successful stent-
ing were randomized to either the standard 18-hour infusion 
of eptifibatide following the procedure, or an abbreviated 
infusion of 2 hours. The primary endpoint (the incidence 
of peri-procedural myonecrosis defined as troponin I 
elevation 0.26 µg/L) was similar between the groups 
(30.1% in the 2-hour group vs 28.3% in the 18-hour group, 
P  0.012 for noninferiority). Moreover, the secondary end-
point (30 day incidence of myocardial infarction, death, and 
target vessel revascularization) was similar between the two 
groups (4.5% vs 4.8%, P = 1.0). Importantly, from a risk-
benefit ratio standpoint, the abbreviated infusion (2-hour) 
resulted in significantly decreased rates of major bleeding 
complications compared to the standard 18-hour infusion 
(1.0% vs 4.2%, P = 0.02).
The short-term effects of bolus-only administration 
of abciximab, tirofiban, and eptifibatide have also been 
studied.78–82 These studies have suggested that bolus-only 
platelet glycoprotein IIb/IIIa inhibitors are as effective 
as the standard bolus and infusion protocol, but are 
associated with better clinical outcomes. Additional trials 
assessing the role (and perhaps length of administration) 
of platelet glycoprotein IIb/IIIa inhibitors in ACS patients 
undergoing PCI in the setting of clopidogrel pretreatment 
are needed.
Role of heparin
The benefit of using unfractionated heparin in the treatment 
of ACS was first documented more than 20 years ago,83 and 
subsequently, its use has been shown to result in a 33% rela-
tive risk reduction in death or myocardial infarction when 
prescribed in addition to aspirin.84 In patients with ACS 
undergoing an initial invasive strategy, both unfractionated Vascular Health and Risk Management 2009:5 683
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heparin and low-molecular-weight heparin carry a Class I 
indication (level of evidence: A).37 However, the limitations 
of unfractionated heparin as described above have led inves-
tigators to explore the use of low-molecular-weight heparin 
instead. One of the first studies to evaluate low-molecular-
weight heparin in patients with ACS was the Efficacy and 
Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary 
Events Study Group (ESSENCE) trial.85 The ESSENCE 
trial compared the use of the low-molecular-weight heparin, 
enoxaparin, to unfractionated heparin in patients with ACS 
undergoing PCI. Patients randomized to enoxaparin had 
lower rates of the composite endpoint of death, myocardial 
infarction, or recurrent angina compared to patients treated 
with unfractionated heparin at 14 days (16.6% vs 19.8%, 
P = 0.019), and at 30 days (27.9% vs 32.2%, P = 0.001). 
Moreover, this benefit was maintained at 1-year follow-up 
(32.0% vs 35.7%, P = 0.002).29 The TIMI-IIb trial confirmed 
the benefit of enoxaparin in patients with ACS.86 There was a 
significant reduction in the primary endpoint (a composite 
of death, myocardial infarction, or urgent revascularization 
at 8 days and at 43 days) in patients treated with enoxaparin 
versus unfractionated heparin (12.4% vs 14.5%, P = 0.048). 
A meta-analysis combining data from both the ESSENCE 
and TIMI-IIb trials showed a reduction in death and ischemic 
events for patients receiving enoxaparin at day 8 (OR 0.77, 
95% CI 0.62–0.95, P = 0.02), which persisted through 
follow-up at 14 days (OR 0.79, 95%CI 0.65–0.96, P = 0.02) 
and at 43 days (OR 0.82, 95% CI 0.69–0.97, P = 0.02).87
The more recent Superior Yield of the New Strategy 
of Enoxaparin, Revascularization and Glycoprotein IIb/
IIIa inhibitors (SYNERGY) trial which randomized 10,027 
high-risk patients with non-STEMI to either enoxaparin or 
unfractionated heparin prior to an early invasive approach, 
found no significant difference in the primary endpoint of all-
cause death or nonfatal myocardial infarction during the first 
30 days after randomization between the groups (14.0% vs 
14.5%, P = NS).88 While no differences in the rates of bleeding 
have been reported in patients receiving unfractionated vs 
enoxaparin who undergo an initial conservative approach,89,90 
the SYNGERY trial reported an increase in TIMI major 
bleeding in patients receiving enoxaparin (9.1% vs 7.6%, 
P = 0.008).88 A meta-analysis comparing unfractionated 
heparin to low-molecular-weight heparin in patients with ACS 
revealed no significant difference in the risk of major bleeding 
with the short-term use of both unfractionated heparin vs pla-
cebo (OR 1.88, 95% CI 0.60–5.87, P = 0.28) and low molecular 
weight vs placebo (OR 1.41, 95% CI 0.62–3.23). However, 
long-term use of unfractionated heparin was associated 
with a significant increase in major bleeding (OR 2.26, 95% 
CI 1.63–3.14, P  0.0001) which was equivalent to an excess 
of 12 major bleeds for every 1000 patients treated.90 Pooled 
data from 21,946 patients in 6 trials comparing unfractionated 
heparin to low-molecular-weight heparin in patients with 
ACS showed no significant difference in death at 30 days for 
enoxaparin vs unfractionated heparin (3.0% vs 3.0%, OR 1.00, 
95% CI 0.85–1.17).91 However, the combined endpoint of 
death or nonfatal infarction at 30 days was significantly lower 
for patients treated with enoxaparin rather than unfractionated 
heparin (10.1% vs 11.0%, OR 0.91, 95% CI 0.83–0.99). 
Importantly, there was no significant difference in rates of blood 
transfusions (OR 1.01, 95% CI 0.89–1.14) or major bleeding 
(OR 1.04, 95% CI 0.83–1.30) at 7 days after randomization.
Nonetheless, the inability to measure the level of antico-
agulant therapy with the activated clotting time in patients 
receiving low-molecular weight-heparin generates reluctance 
by interventional cardiologists to use it during PCI. The 
widespread use of low-molecular-weight heparin in ACS 
patients before angiography, however, makes this issue 
unavoidable. Guidelines for the use of enoxaparin in the 
peri-PCI period have been proposed.37,92 These guidelines 
state that if enoxaparin is to be used as the antithrombotic 
agent during the PCI procedure, no additional amount should 
be given if the last dose was administered within 8 hours. 
If the last subcutaneous dose was administered at least 
8 to 12 hours earlier, an intravenous dose of 0.3 mg/kg of 
enoxaparin should be given. An 8-hour window after the last 
dose of low-molecular-weight heparin is preferred prior to 
switching to unfractionated heparin.93
A unique treatment strategy using low dose enoxaparin 
(0.50 mg/kg every 12 hours) prior to PCI in conjunction 
with dual antiplatelet therapy (aspirin and clopidogrel) 
followed by triple antiplatelet therapy (aspirin, clopidogrel 
and eptifibatide) during the PCI has been evaluated in a large, 
single center study.94 The analysis included 1400 consecutive 
patients and found that this treatment strategy was associ-
ated with low rates of acute ischemic events (1.8%), minor 
bleeding complications (2.1%), major bleeding complications 
(0.1%), thrombocytopenia (1.3%), and major adverse clinical 
events (0.4%); suggesting the need for a randomized clinical 
trial to further evaluate this approach.94
Despite improved bioavailability and predictable weight-
based dosing, there are several patient populations where 
pharmacologic parameters for low-molecular-weight heparin 
are altered including patients with renal insufficiency, the 
elderly, and the obese.95 Patients who are obese have less lean 
body mass as a percentage of total body weight, so dosing Vascular Health and Risk Management 2009:5 684
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low-molecular-weight heparin according to total body 
weight can cause supra-therapeutic anticoagulation. A similar 
problem arises in the elderly who also have less lean body 
mass (in addition to other complicating factors such as renal 
insufficiency). Since the kidneys are the primary route of 
elimination for low-molecular-weight heparin, patients with 
impaired renal function, particularly with CrCl  30 ml/min are 
at risk for accumulation of  the drug, increased levels of  anti-Xa, 
and increased risk of major bleeding complications.96,97 
In general, the use of low-molecular-weight heparin should 
be avoided in patients with CrCl  30 ml/min.
Role of factor Xa inhibitor
The safety and efficacy of the novel factor Xa inhibitor, 
fondaparinux, was evaluated in the Organization to Assess 
Strategies in Acute Ischemic Syndromes (OASIS)-5 trial.38 In 
this trial 20,078 patients with unstable angina or non-STEMI 
were randomized to enoxaparin 1.0 mg/kg every 12 hours 
or to fondaparinux 2.5 mg daily. The primary outcome 
(a composite of death, myocardial infarction, or refractory 
ischemia at 9 days) occurred in 5.7% of those randomized to 
enoxaparin and 5.8% of those randomized to fondaparinux 
(hazard ratio 1.01, 95% CI 0.90–1.13, P = 0.007 for nonin-
feriority). Moreover, major bleeding complications were sig-
nificantly less in the patients receiving fondaparinux (2.2% vs 
4.1%, P  0.001). However, in the patients who underwent 
PCI, those who were treated with fondaparinux had a sig-
nificant increase in rates of catheter thrombosis compared 
to those treated with enoxaparin (0.9% vs 0.4%, P = 0.001) 
which was believed to be from the inability of fondaparinux 
to block pre-existing thrombin. Therefore, because of the 
risk of catheter thrombosis, fondaparinux should not be used 
as the sole anticoagulant during PCI in patients with STEMI 
(Class III indication, level of evidence: C); unfractionated 
heparin should be concomitantly administered.98
The use of fondaparinux in patients with non-STEMI and 
unstable angina who undergo both an initial conservative or 
invasive management strategy carries a Class I indication 
(level of evidence: B) according to the ACC/AHA guidelines.37 
Similar to low-molecular-weight heparin, fondaparinux is 
excreted by the kidneys and therefore is contraindicated in 
patients with a CrCl  30 ml/min.37
Role of bivalirudin
In addition to low-molecular-weight heparin, bivalirudin has 
also been studied as a replacement for unfractionated heparin 
in patients with ACS undergoing PCI and carries a Class I 
(level of evidence:B) indication for use in these patients.37 
One of the first studies to evaluate the use of bivalirudin in 
PCI randomized 4098 patients to receive either unfraction-
ated heparin or bivalirudin during the procedure.99 While 
there was no difference in the primary endpoint (a composite 
of death, myocardial infarction, abrupt vessel closure, 
or rapid clinical deterioration of cardiac origin), patients 
randomized to bivalirudin had significantly lower rates of 
bleeding compared to patients randomized to unfractionated 
heparin (3.8% vs 9.8%, P  0.001).
With the introduction of more potent antiplatelet agents 
like clopidogrel and platelet glycoprotein IIb/IIIa inhibitors, 
several trials have examined the safety and efficacy of bivali-
rudin in conjunction with these medications. In a pilot trial 
called the Comparison of Abciximab Complications with 
Hirulog for Ischemic Events (CACHET) trial, 268 patients 
were randomized to receive bivalirudin (with or without 
abciximab) or abciximab with low-dose weight-adjusted 
heparin during PCI.100 In this study, bivalirudin with planned 
or provisional abciximab was as safe and effective as low-dose 
heparin plus abciximab. In a separate trial called the Protection 
against Post-PCI Microvascular Dysfunction and Post-PCI 
Ischemia among Anti-Platelet and Anti-Thrombotic Agents-
Thrombolysis in Myocardial Infarction (PROTECT-TIMI)-
30 trial, 857 patients with non-STEMI were randomized to 
one of three regimens following angiography: eptifibatide + 
reduced-dose unfractionated heparin, eptifibatide + reduced 
dose low-molecular-weight heparin, or bivalirudin mono-
therapy.101 The primary endpoint, coronary flow reserve, was 
greater in the bivalirudin arm compared to pooled data from 
the two different eptifibatide arms (1.43 vs 1.33, P = 0.036). 
However, TIMI myocardial perfusion grade was more often 
normal in patients treated with eptifibatide compared to 
bivalirudin (57.9% vs 50.9%, P = 0.048), and the duration 
of ischemia on Holter monitoring after PCI was significantly 
longer in patients treated with bivalirudin (169 min vs 36 min, 
P = 0.013). Although there was no excess of TIMI major 
bleeding in patients treated with eptifibatide compared with 
bivalirudin (0.7% vs 0%, P = NS), TIMI minor bleeding was 
increased (2.5% vs 0.4%, P = 0.027) as well as blood transfu-
sion requirements (4.4 % vs 0.5%, P  0.001).
The ACUITY study examined the use of bivalirudin in 
13,819 moderate-risk and high-risk patients with ACS under-
going an early invasive strategy.102 Patients were randomized to 
one of three regimens: platelet glycoprotein IIb/IIIa inhibitor + 
unfractionated heparin or low-molecular-weight heparin; 
platelet glycoprotein IIb/IIIa + bivalirudin; or bivalirudin 
alone. Bivalirudin + platelet glycoprotein IIb/IIIa inhibitor, 
as compared to heparin + platelet glycoprotein IIb/IIIa, Vascular Health and Risk Management 2009:5 685
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was associated with similar rates of the composite ischemic 
endpoint of death, myocardial infarction, or unplanned revas-
cularization (7.7% vs 7.3%, P = NS); major bleeding (5.3% vs 
5.7%, P = NS); and the net clinical endpoint of ischemia or 
major bleeding (11.8% vs 11.7%, P = NS). In addition, bivali-
rudin alone, as compared to heparin + platelet glycoprotein 
IIb/IIIa inhibitor, was associated with similar rates of the 
composite ischemic endpoint (7.8% vs 7.3%, P = 0.32), and 
significantly reduced rates of major bleeding (3.0% vs 5.7%, 
P  0.001), and the net clinical endpoint (10.1% vs 11.7%, 
P = 0.02). In a subgroup analysis of this trial that evaluated 
7789 patients who underwent PCI, there were no differences 
in the composite endpoint of death, myocardial infarction, 
unplanned revascularization, or death at one year.103 However, 
there was a significant reduction in major bleeding in those 
patients who received bivalirudin alone compared to those 
who received heparin + platelet glycoprotein IIb/IIIa inhibitors 
(4.0% vs 7.0%, P  0.001). In a separate analysis of the 
ACUITY trial, patients who were switched to bivalirudin 
from either unfractionated or low-molecular-weight heparin 
had similar rates of ischemia (6.9% vs 7.4%, P = 0.52), but 
less major bleeding complications (2.8% vs 5.8%, P  0.01), 
which resulted in improved net clinical outcomes (9.2% vs 
11.9%, P  0.01) compared to those who remained on unfrac-
tionated heparin or low-molecular-weight heparin + platelet 
glycoprotein IIb/IIIa inhibitors.104
Lastly, the Harmonizing Outcomes with Revasculariza-
tion and Stents in Acute Myocardial Infarction (HORIZONS-
AMI) trial randomized 3602 patients with STEMI to 
heparin + platelet glycoprotein IIb/IIIa or bivalirudin alone.105 
Anticoagulation with bivalirudin was associated with a 24% 
absolute risk reduction in the net adverse clinical events 
(major bleeding or major adverse cardiac events includ-
ing death, re-infarction, target vessel revascularization 
for ischemia, and stroke) at 30 days (9.2% vs 12.1%, RR 
0.76, 95% CI 0.63–0.92, P = 0.0005) with a 40% absolute 
reduction in major bleeding (4.9% vs 8.3%, RR 0.60, 95% 
CI 0.46–0.77, P  0.001). One important caveat regarding 
the results of this trial is that there was an increased risk of 
acute stent thrombosis within 24 hours in patients treated 
with bivalirudin (0.3% vs 1.3%, P  0.001). It has been 
suggested that one contributing factor could have been 
inadequate pretreatment with clopidogrel. This concern was 
addressed in a post-hoc analysis of the 7789 patients in the 
ACUITY trial that underwent PCI:106 when clopidogrel was 
administered prior to the PCI or within 30 minutes after the 
PCI, bivalirudin therapy alone was associated with similar 
ischemic outcomes compared to placebo (8.2% vs 8.3%, 
RR 0.98, 95% CL 0.81–1.20, P = 0.88). However, in patients 
who received clopidogrel either 30 minutes after the PCI or 
not at all, there was a significant increase in ischemic events 
in patients randomized to bivalirudin compared to placebo 
(14.1% vs 8.5%, RR 1.66, 95% CI 1.05–2.63, P = 0.03).
The prevailing theme of the importance of optimal 
clopidogrel pretreatment is also evident in trials assessing 
the safety and efficacy of bivalirudin in patients with ACS 
undergoing PCI.107,108 In the Intracoronary Stenting and 
Antithrombotic Regimen: Rapid Early Action for Coronary 
Treatment (ISAR-REACT) 3 study,107 the use of bivalirudin 
in patients with stable or unstable angina undergoing PCI 
was evaluated. In this trial 4570 patients who were optimally 
pretreated with 600 mg of clopidogrel were randomized to 
either bivalirudin or unfractionated heparin at the time of the 
PCI procedure. While there was no difference in the primary 
endpoint (a composite of death, myocardial infarction, and 
target vessel revascularization due to myocardial ischemia 
at 30 days), there was a lower incidence of major bleeding 
in the bivalirudin group (4.6% vs 3.1%, P = 0.0008). In the 
Randomized Evaluation of PCI Linking Angiomax to Reduced 
Clinical Events (REPLACE)-2 trial 6010 patients undergoing 
elective or urgent PCI were randomized to bivalirudin with 
provisional platelet glycoprotein IIb/IIIa inhibitor, or to hepa-
rin with planned platelet glycoprotein IIb/IIIa inhibitor.108 
Importantly, greater than 84.9% of patients received 
pre-treatment with clopidogrel (26.6% received clopidogrel 
2 hours prior to PCI and 56.7% received it between 
2–48 hours prior of PCI). Similar to the ISAR-REACT 3 study, 
there was no difference in the primary endpoint of death, 
myocardial infarction, or urgent repeat revascularization at 30 
days, and in-hospital major bleeding rates were significantly less 
with bivalirudin than the combination of heparin and platelet 
glycoprotein IIb/IIIa inhibitor (2.4% vs 4.1%, P  0.001).
What agents should be used?
The combination of a large variety of antithrombotic 
medications available (Table 1), and the lack of consensus 
regarding the optimal regimen for any given patient, has 
resulted in a long list of potential regimens. There must be a 
balance between choosing the regimen that will minimize the 
risk of recurrent ischemic events, and one that will minimize 
the risk of bleeding.9 Considering the overall risk-benefit 
ratio, therefore, is important in the decision-making process 
since it may guide the physician to choose one particular 
antithrombotic regimen over another for any given patient.109 
Several risk assessment algorithms are available to help the 
physician gauge whether the patient is at high- or low-risk for Vascular Health and Risk Management 2009:5 686
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a recurrent cardiac event including the TIMI risk score,110 the 
Global Registry of Acute Coronary Events (GRACE) score,111 
and the Platelet Glycoprotein IIb/IIIa in Unstable Angina: 
Receptor Suppression Using Integrilin Therapy (PURSUIT)112 
(Figure 1). In addition to the risk of a recurrent ischemic 
event, there are other important factors that should be taken 
into consideration (Table 2): (1) the risk of bleeding, (2) the 
timing and dose of clopidogrel prior to PCI (if administered), 
(3) the timing and dose of low-molecular-weight heparin 
prior to PCI (if administered), (4) the patient’s renal function, 
and (5) whether the patient has a history of heparin-induced 
thrombocytopenia, or previous drug reactions.
Recently, the Can Rapid Risk stratification of Unstable 
Angina Patients Suppress Adverse Outcomes with Early 
Implementation of the ACC/AHA Guidelines (CRUSADE) 
bleeding score has been developed and validated.113 This 
score predicts the baseline risk of in-hospital major bleeding 
and incorporates patient information that is readily available 
upon admission: patient factors predictive of  in-hospital major 
bleeding are female gender, diabetes, a history of vascular 
disease, high or low systolic blood pressure, tachycardia, 
hematocrit 36%, and renal insufficiency. Advanced age 
has also been shown to be a risk factor for major bleed-
ing complications.114 However, since no current algorithm 
Table 1 Antithrombotic agents commonly administered to patients 




  Thienopyridine (clopidogrel)
  Platelet glycoprotein iib/iiia inhibitors
Anticoagulant
  indirect thrombin inhibitors
    Unfractionated heparin
    Low molecular weight heparin
  Direct thrombin inhibitor (bivalirudin)
  Factor Xa inhibitor (fondaparinux)
Factors
Age  65
3 CAD risk factors
Known CAD (stenosis   50%)
Aspirin use in past 7 days
>1 episode of rest pain in <24 hours
Elevated cardiac enzymes





























































































































Figure 1 The TiMi, PURSUiT, and GRACe risk scores.
Abbreviations: CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; CHF, congestive heart failure; Mi, myocardial infarction; PCi, percutaneous coronary 
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incorporates both ischemic and bleeding risk, creation of a 
“bleeding risk subscale” has been proposed.115 Moreover, 
these investigators recommend particular anthithrombotic 
agents by integrating bleeding risk with specified ranges of the 
TIMI, PURSUIT, and GRACE risk scores that define patients 
at low (defined as TIMI 0–2, PURSUIT 0–8, GRACE 0–124); 
moderate (defined as TIMI 3–4, PURSUIT 9–16, GRACE 
125–248); and high (defined as TIMI 5–7, PURSUIT 17–25, 
GRACE 249–372) ischemic risk. We similarly propose an 
algorithm, but include not only cardiac and bleeding risk, but 
also whether the patient has been pretreated with clopidogrel 
(Figure 2). In patients who are pretreated with clopidogrel, 
there are many acceptable choices for an antithrombotic 
regimen during PCI, especially when the bleeding risk is 
low. The more difficult scenario, however, is when the patient 
has not been pretreated with clopidogrel, and is at high risk 
for a bleeding complication: in this case, if bivalirudin is 
used, a loading dose of clopidogrel should be administered 
as soon as possible in the cardiac catheterization laboratory 
to decrease the risk of subacute stent thrombosis. Moreover, 
if a platelet glycoprotein IIb/IIIa inhibitor is needed on a 
provisional basis, a short-acting agent would be preferable.
Future prospects
Novel agents primarily used for prevention of venous 
thromboembolism are currently being investigated for 
Table 2 Key considerations in selecting the optimal antithrombotic 
regimen for an individual patient




Risk of major bleeding Consider
CRUSADe bleeding score
Clopidogrel pretreatment Yes or no
if yes, determine timing and 
dose of administration prior 
to PCi procedure
Enoxaparin pretreatment Yes or no
if yes, determine timing and 
dose of administration prior 
to PCi procedure
Renal insufficiency Yes or no
if yes, follow recommended 
renal dosinga
Heparin-induced thrombocytopenia Yes or no
   if yes, tailor regimen accordingly, 
use bivalirudin in place of heparin
aintegrilin, fondaparinux and enoxaparin should be avoided in patients with severe 
renal insufficiency (creatinine-clearance 30 mL/min).
Abbreviations: CRUSADe, Can Rapid Risk Stratification of Unstable Angina 
Patients Suppress Adverse Outcomes with early implementation of the   ACC/AHA 
Guidelines;112 GRACe, Global Registry of Acute Coronary events;110 PURSUiT, Platelet 
Glycoprotein iib/iiia in Unstable Angina: Receptor Suppression Using integrilin  Therapy;111 










GpIIb/IIIa inhibitor + UFH
without clopidogrel:
GpIIb/IIIa inhibitor + UFH
without clopidogrel:


























Figure 2 Algorithm for selecting the optimal antithrombotic regimen incorporating cardiac risk, bleeding risk, and clopidogrel pretreatment. in this algorithm it is assumed 
that all patients have received aspirin.
*if bivalirudin is used, a loading dose of clopidogrel should be given as soon as possible in the cardiac catheterization laboratory to decrease the risk of subacute stent 
thrombosis.Vascular Health and Risk Management 2009:5 688
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use in patients with ACS.116 In the Anti-Xa Therapy to 
Lower Cardiovascular Events in Addition to Aspirin with 
or without Thienopyridine Therapy in Subjects with Acute 
Coronary Syndrome-Thrombolysis in Myocardial Infarction 
(ATLAS ACS-TIMI) 46 trial, rivaroxaban (an oral direct 
factor Xa inhibitor) was associated with a dose-dependent 
increase in clinically significant bleeding events, with a 
trend towards a reduction in the primary efficacy endpoint 
of death, myocardial infarction, stroke, or severe recurrent 
ischemia requiring revascularization.117 Similar findings 
have been published regarding apixaban, also an oral direct 
factor Xa inhibitor evaluated in the Apixaban for Preven-
tion of Acute Ischemic Events (APPRAISE) trial.118 Lastly, 
dabigatron, an oral direct thrombin inhibitor is being studied 
in the context of secondary prophylaxis after myocardial 
infarction in the placebo-controlled phase II Randomized 
Dabigatron Dose Finding Study in Patients with Acute 
Coronary Syndromes Post Index Event with Additional Risk 
Factors for Cardiovascular Complications Also Receiving 
Aspirin and Clopidogrel: Multi-Centre, Prospective, Placebo 
Controlled, Cohort Dose Escalation (RE-DEEM) trial.119
Conclusion
Selecting the appropriate antithrombotic regimen for 
patients with ACS undergoing PCI has become a complex 
task. Treatment guidelines are needed to help physicians 
incorporate cardiac risk, bleeding risk, and other key factors 
into their selection of the optimal antithrombotic regimen for 
an individual patient.
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